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At least 15 types of high oncogenic risk human papillomavirus
(HPVhr) DNA have been detected in the uterine cervix (Lorincz
et al, 1992). Most infections with these viruses regress sponta-
neously, but in a small proportion of women infection can become
persistent and lead to the development of precancerous lesions
(cervical intraepithelial neoplasia grades 2 and 3, CIN2/3 or HSIL)
and ultimately cancer. Since the risk of cervical cancer is popula-
tion- (IARC, 1995) and HPV type-dependent (Lorincz et al, 1992),
specific viral and/or local host co-factors are believed to be neces-
sary for the development of precancer and cancer.
Previously we found that HPV16, 18, 31 and 33 were common
in CIN2/3 lesions in British women (Cuzick et al, 1994) but the
prevalence of different HPVhr in invasive cervical cancer in the
UK is not known and little Western European data contributed to
the worldwide study of Bosch et al (1995). This information is
required if the role of HPVhr in the oncogenic process is to be
critically assessed in a UK context. Individual variants of a single
HPVhr genotype may also influence the development of disease.
For example, in HPV16 isolates a polymorphism (T/G) at
nucleotide 350 in the E6 gene has been reported to occur more
frequently as G in isolates from CIN2/3 and cervical cancer than in
isolates from low-grade lesions and this is possibly population-
dependent (Zehbe et al, 1998a). Moreover, nt350 G variants are
more likely to persist at high copy number in low-grade lesions
than the prototype virus (nt350T) (Londesborough et al, 1996; Xi
et al, 1997). These results suggest a complex relationship between
this polymorphism and the development of cervical disease; a
failure in E6 antigen presentation has been suggested. The prod-
ucts of the HLA (human leucocyte antigen) class I and class II
genes are highly polymorphic and play a major role in regulating
T-cell responses to foreign antigens, including viral antigens. The
particular alleles inherited by an individual may help to determine
the outcome of certain viral infections. Unfortunately the immuno-
genetic status associated with HPV infections and HPV16 E6
variants determined so far has provided inconclusive results
(Londesborough et al, 1996; Bontkes et al, 1998; Terry et al,
1998). In this study, we have assessed the prevalence of HPV16
and other HPVhr types in British women presenting with cervical
cancer and estimated the frequencies of HPV16 E6 gene polymor-
phisms in isolates. The prevalence of HLA DRB1* and DQB1*
alleles was estimated, compared with a control population and
examined for interaction with HPV types and variants. The impli-
cations of viral and host factors in relation to the cervical cancer
risk are discussed.
PATIENTS AND METHODS
Patients
Cervical scrapes were collected from women (average age ± 1 s.d.
= 50.18 ± 15.81 years) on referral with cervical cancer prior to
treatment from clinics in Britain. The first 116 scrapes found posi-
tive for b-globin DNA by polymerase chain reaction (PCR) were
tested blind. Only histological data were made available to the
study. The scrapes were collected from Scotland (1), North
England (87), Midlands (1) and South-east England (27). One
hundred and fifty-five scrapes collected from normal women as
part of a previous study (Cuzick et al, 1999) from which both
DRB1* and DQB1* alleles could be determined were used as
matched controls in the HLA analysis. These women had normal
cytology and were negative for HPVhr as tested by consensus
PCR/SHARP assay (Digene Corp.) and by HPV16, 18, 31, 33, 35,
58 type-specific PCR (Cuzick et al, 1999).
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DNA preparation
Cells from cervical scrapes were collected in sterile phosphate-
buffered saline (PBS) containing antibiotics and fungizone. After
centrifugation, each pellet was re-suspended and heated to 98°C in
1 ml of sterile PBS for 30 min. Two microliters of the supernatant
was used for either HPV or HLA PCR.
Consensus and type specific PCR for HPV16, 18, 31
and 33
This was carried out as previously described (Cuzick et al, 1999).
HPV16 E6 sequencing
HPV16 E6 sequence was amplified (by nested PCR) as previously
described by Wheeler et al (1997). The quality of the PCR frag-
ments was assessed visually under UV after electrophoresis in
agarose gels. The templates were purified using Wizard PCR
Preps (Promega Corp.). Sequencing reactions were carried out
using chain termination sequencing reactions and Thermo-
sequenase (Amersham Pharmacia Biotech). The following Cy5-
labelled sequencing primers were used:
Forward: 5¢-ATAAAAGCAGACAT-3¢
Reverse: 5¢-TGTAGGTGTATCTCC-3¢.
Reactions were analysed using an automated sequencer
(AlfExpress, Amersham Pharmacia Biotech). HPV16 E6 variants
were identified and confirmed by direct sequencing in both direc-
tions between nucleotides 80 and 567. HPV16r nucleic acid
sequence was used as reference. Sixty-four of the 76 HPV16
isolates yielded identical sequencing results from both directions
and only these were included in the study.
HLA typing
This was carried out by direct sequencing of amplified DRB1*
and DQB1* alleles as previously described (Terry et al, 1998).
Haplotypes were inferred based on known patterns of linkage
disequilibrium in Whites for these loci (Apple et al, 1994; Odunsi
et al, 1996).
Statistical analysis
All  P-values used for comparing the number of cancers and
controls who were positive for a specific allele or haplotype were
two-sided Fisher exact values (obtained from doubling one-sided
values). All confidence intervals (CI) are 95% coverage intervals.
The analysis was carried out using the SAS statistics package.
RESULTS
HPV genotypes
The HPV genotypes associated with cancer of different histology
are shown in Table 1. Of the 116 cancer samples tested, 109 (94%)
were found to be positive for HR types. Six lesions contained two
HPV types. HPV16 was found in 66% of all cancers and was far
more common than other types (HPV18 10%, HPV31 9%, HPV33
4% and other HPVhr types 4%) (Table 1).
HPV16 polymorphism in E6
The sequencing results are shown in Table 2. HPV subtype desig-
nations are as given by Yamada et al (1995). Nt350T subtypes
were found in 58% of all HPV16-positive cancers (31 had E-350T,
three had AF) while 42% of isolates had nt350 G (16 had E-350 G,
two had E131 G, five had AA and two had NA1). This is not
significantly different from our previous study where nt350T and
nt350G subtypes were found respectively in 57% and 43% of 14
women who had a normal cervix at both initial and follow-up
visits (Londesborough et al, 1996).
HLA alleles and haplotypes
Table 3 summarizes the data for the HLA DQB1* and DRB1*
alleles from the 116 cancers and 155 controls which occur at
frequencies equal to or greater than 2% in the control population.
HLA typing by nucleic acid sequencing as reported here is not
carried out routinely in the UK and it is not known if the allelic
frequencies observed in our control population are representative
of the general British population. Frequencies of common alleles
(those which occur at ³ 10%) are similar to those previously
reported for the UK female population (Duggan-Keen et al, 1996;
Odunsi et al, 1996). DQB1*0301 (2P = 0.02, odds ratio (OR) =
1.67, CI = 1.06–2.65) was found to be associated with cervical
cancer and this association is stronger in cancers positive for HPV
types other than HPV16 (2P = 0.006, OR = 2.54, CI = 1.30–4.92).
In contrast, DQB1*1501 was not elevated in cancer overall, but a
relationship with HPV16-positive cancer was suggestive (2P =
0.05, OR = 1.73, CI = 0.99–3.03). A marginally significant protec-
tive effect was found for DQB1*0501 (2P = 0.03, OR = 0.53, CI =
0.29–0.96), but not for DRB1*1301. No significant change in
cancer risk was detected in women homozygous for any of these
alleles.
An analysis of the DRB1*/DQB1* assigned haplotypes occur-
ring at frequencies equal to or greater than 2% in the controls
(Table 3) identified six frequently occurring DRB1*/DQB1*
Table 1 Prevalence of HR-HPV genotypes in British women diagnosed with cervical cancer
Histology No. tested No. with HR-HPV No. without HR-HPV
Any HR-HPV HPV16 HPV18 HPV31 HPV33 Others
Adenocarcinoma 19 16 8 6 2 0 0 3
Adeno-squamous carcinoma 12 10 6 2 2 0 0 2
Squamous carcinoma 85 83 62 4 7 5 5 2
Total (%) 116 (100) 109 (94) 76 (66) 12 (10) 11 (9) 5 (4) 5 (4) 7 (6)
Six double infections with HPV16 and one other HR-HPV type are counted only once under HPV16.1350 J Cuzick et al
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haplotypes in our control population – 0101/0501, 0301/0201,
0401/0301, 0701/0201, 1101/0301 and 1501/0602. Only
0401/0301 showed a clear association with cervical cancers taken
as a whole (2P = 0.02, OR = 2.40, CI = 1.12–5.22). This same
haplotype was also found to be associated with cancers positive for
HPVhr types other than HPV16 (2P = 0.001, OR = 4.75, CI =
1.84–12.21) in keeping with the results for the constituent alleles.
In contrast, DRB1*/DQB1* haplotype 1501/0602 was found to be
weakly associated only with cancers positive for HPV16 (2P =
0.05, OR = 1.81, CI = 1.00–3.29).
The association of HPV16 European isolates
polymorphic at E6 nt350 with DRB1* and DQB1* alleles
No significant differences in the HLA frequencies in HPV16
E350G/T variants could be found, possibly due to limitations in
sample size. However the T variant occurred more frequently than
the G variant in women with DRB1*1501 (15 T to 4 G, 2P = 0.17),
DQB1*0602 (17 T to 5 G, 2P = 0.15) alleles, or with the corre-
sponding haplotype 1501/0602 (15 T to 3 G, 2P = 0.07) which
suggests this might be worth studying further.
DISCUSSION
HPVhr was detected in 94% of the scrapes from women who had
cervical cancer and 66% were HPV16 (Table 1). The percentage of
HPVhr genotypes which are HPV16 observed in cancer is
markedly different from that in the normal British screening popu-
lation aged over 35 years (Cuzick et al, 1999). This indicates that
HPV16 is not only more prevalent than other HPVhr types in the
UK, but is also more oncogenic. How the oncogenic process
relates to an evasion of the host immune surveillance mechanism
is not clear.
The immunogenetics of HLA DRB1* and DQB1* in associa-
tion with HPV16 and other HPVhr positive cervical intra-epithelial
neoplasms (CIN) and cancer has been investigated in many studies
but the results obtained so far have been inconsistent. This has
usually been attributable to population differences or to whether
cytology, serology or nucleic acid-based methods were used to
determine the HPV and/or HLA status (Wank et al, 1992; Apple
et al, 1994, 1995; Duggan-Keen et al, 1996; Odunsi et al, 1996;
Sanjeevi et al, 1996; Bontkes et al, 1998; Helland et al, 1998;
Hildesheim et al, 1998), but chance association among the
multiple comparisons performed may also be an important factor.
We have used well-characterized, consistent analytical methods
throughout this study. HPVhr genotypes were determined by both
type-specific PCR and consensus PCR/SHARP using probes for
HPVhr types. This is to ensure vigorously that all women in the
control population are HPVhr-negative. HPV16 E6 sequences and
HLA types were determined precisely by nucleic acid sequencing.
However, chance is still an important source of error especially for
comparisons between HPVhr types where the numbers are small.
Also there is a geographic disparity between our cancer cases
(mostly northern England) and controls (mostly southern
England). Since the frequencies of the commonly occurring alleles
in our normal control population reported here are consistent with
those we reported previously for women from southern England
(Odunsi et al, 1996) and to those reported for northern England
(Duggan-Keen et al, 1996), the gene pools appear to be similar.
The most commonly reported HLA alleles in association with
cervical cancer overall is DQB1* 03 (Wang et al, 1992) and we
also obtained the most significant findings for this allele. In this
study, we identified the most important at-risk allele as
DQB1*0301 (OR = 1.67, CI = 1.06–2.65) with the risk of cancer
being further increased when DRB1*0401 is also present. We have
previously found these same alleles to be associated respectively
with HPV16-, 18-, 31- and 33-positive CIN lesions from the UK
(DQBI*0301 OR = 2.77, DRB1*0401 OR = 2.34, 0401/0301
OR = 2.88) (Odunsi et al, 1996). In a Puerto Rican population,
Hildesheim et al, (1998) associated HPV16-positive lesions with
DQB1*0302. It seems clear that DQB1*03 plays an important role
in the pathogenesis of cervical cancer and CIN2/3. In contrast,
DQB1*0501 but not DRB1*1301 was found to have the protective
effect (Table 3) found by other workers (Apple et al, 1994; Odunsi
et al, 1996). Failure to find a significant association with
DRB1*1301 may be due to the rarity of the allele in our sample
and to the relatively small sample size.
Table 2 HPV16 E6 polymorphic sites in isolates from cervical cancers
HPV16 No. of % of
subtype templates total E6 nucleotides
131 132 143 145 183 257 286 289 310 314 335 350 369 532
Prototype A G C G T A T A T T C T A A
E-350T 28 53
1 G
1 G
1 G
E-350G 14 27 G
1G G
1 GG
E131G 2 3 G G
AF 1 5 C G T G G T
2C G T A G T
AA 3 8 T A G T G G
1 AG T G G
1T G A G T G G
NA1 2 3 T A G T G
HPV subtype designations are from Wheeler et al (1997).HPV, HLA and cervical cancer in British women 1351
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Consistent with a previous report (Apple et al, 1994), our results
show a small risk of DRB1*1501 allele (OR = 1.73) and the
DRB1*/DQB1* haplotype 1501/0602 (OR = 1.81) in women with
HPV16-positive cancers (Table 3). This estimate is smaller than
the high cancer risk (OR = 4.78) found for this haplotype in a study
of Hispanic women (Apple et al, 1994). In addition we found this
haplotype occurring fivefold more frequently in women with
cervical cancers positive for the E350T rather than E350G variant,
although the statistical significance has yet to be confirmed
(2P = 0.058).
As in the case of cervical cancers overall, we found cancers
positive for HPV types other than HPV16 to be strongly associated
with DRB1*0401 and DQB1*0301 alleles and the corresponding
haplotype. CIN lesions positive for these HPV types have also
been associated with DQB1*0301 (Odunsi et al, 1994; Sanjeevi
et al, 1996).
In conclusion, we find that in a British population virtually all
cervix cancers are HPV-positive and HPV16 is by far the most
common type. The HLA DQB1*0301 allele confers an increased
risk for cervical cancer regardless of the type of HPV involved.
There is some evidence that HLA DRB1*/DQB1* haplotype
1501/0602 confers an increased risk, possibly restricted to
HPV16-positive cervical cancer. A very large population-matched
study of women with and without cancer is needed to fully eval-
uate any risk related to interactions between HPV type or sequence
variants and HLA alleles.
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